IL117610A - Crystal forms of form ii olanzapine and process for their preparation - Google Patents

Crystal forms of form ii olanzapine and process for their preparation

Info

Publication number
IL117610A
IL117610A IL11761096A IL11761096A IL117610A IL 117610 A IL117610 A IL 117610A IL 11761096 A IL11761096 A IL 11761096A IL 11761096 A IL11761096 A IL 11761096A IL 117610 A IL117610 A IL 117610A
Authority
IL
Israel
Prior art keywords
olanzapine
preparation
crystal forms
crystal
forms
Prior art date
Application number
IL11761096A
Other languages
English (en)
Other versions
IL117610A0 (en
Original Assignee
Lilly Co Eli
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL117610(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Lilly Industries Ltd filed Critical Lilly Co Eli
Publication of IL117610A0 publication Critical patent/IL117610A0/xx
Publication of IL117610A publication Critical patent/IL117610A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
IL11761096A 1995-03-24 1996-03-22 Crystal forms of form ii olanzapine and process for their preparation IL117610A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (2)

Publication Number Publication Date
IL117610A0 IL117610A0 (en) 1996-07-23
IL117610A true IL117610A (en) 2001-08-26

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11761096A IL117610A (en) 1995-03-24 1996-03-22 Crystal forms of form ii olanzapine and process for their preparation

Country Status (49)

Country Link
US (1) US5736541A (de)
EP (3) EP0733635B1 (de)
JP (1) JPH11502535A (de)
KR (1) KR100399688B1 (de)
CN (1) CN1065536C (de)
AP (1) AP828A (de)
AR (2) AR002719A1 (de)
AT (4) ATE331719T1 (de)
AU (1) AU706471B2 (de)
BG (1) BG62619B1 (de)
BR (1) BR9607790A (de)
CA (1) CA2214005C (de)
CH (1) CH690579A5 (de)
CO (1) CO4650278A1 (de)
CZ (1) CZ292688B6 (de)
DE (4) DE69614426T2 (de)
DK (4) DK1445259T3 (de)
EA (1) EA000149B1 (de)
EE (1) EE03489B1 (de)
EG (1) EG23659A (de)
ES (3) ES2208220T3 (de)
FI (1) FI973750A0 (de)
GB (1) GB2313835B (de)
HK (1) HK1013988A1 (de)
HU (1) HU224989B1 (de)
IL (1) IL117610A (de)
IS (1) IS1896B (de)
LT (1) LT4349B (de)
LU (1) LU90096B1 (de)
LV (1) LV12018B (de)
MY (1) MY114701A (de)
NO (1) NO314663B1 (de)
NZ (1) NZ306110A (de)
OA (1) OA10510A (de)
PA (1) PA8353701A1 (de)
PE (1) PE44897A1 (de)
PL (1) PL183723B1 (de)
PT (3) PT733635E (de)
RO (1) RO118872B1 (de)
SE (1) SE9703205L (de)
SI (4) SI0733635T1 (de)
SK (1) SK284143B6 (de)
SV (1) SV1996000031A (de)
TR (1) TR199701017T1 (de)
TW (2) TW513432B (de)
UA (1) UA44765C2 (de)
WO (1) WO1996030375A1 (de)
YU (1) YU49478B (de)
ZA (2) ZA962342B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1997011700A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Method for treating a tic disorder
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
NZ332039A (en) * 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
PL329221A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Method of relieving hemicrania pains
WO1997035583A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
RS49597B (sr) * 1996-09-23 2007-06-04 Eli Lilly And Company, Olanzapin dihidrat d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
EP1155696B1 (de) * 1997-04-15 2004-03-03 Eli Lilly And Company Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
PT1468689E (pt) * 1998-09-30 2007-07-09 Lilly Co Eli Formulação de 2-metil-tieno-benzodiazepina.
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
CA2395774C (en) * 1999-12-28 2009-09-15 Cipla Limited New polymorphic forms of olanzapine
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
AU2001243475A1 (en) * 2000-08-31 2002-03-13 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
WO2003037903A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
CA2471341C (en) * 2001-12-24 2012-01-24 Sun Pharmaceutical Industries Limited Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1490090A4 (de) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Wirkstoff-abgabesystem und verfahren zum schutz und zur verabreichung von wirkstoffen
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
SI1513846T1 (sl) * 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
PT1507531E (pt) * 2003-03-12 2007-03-30 Teva Pharma Composições farmacêuticas estáveis de desloratadina
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005049090A2 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
PT1611139E (pt) * 2003-12-22 2008-07-17 Teva Pharma Métodos de preparação de olanzapina
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
EP1838716B1 (de) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapinpamoat-dihydrat
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
US20100174066A1 (en) * 2005-03-21 2010-07-08 Venkataraman Sundaram Process for preparing crystalline form i of olanzapine
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (de) * 2005-08-17 2008-05-14 Synthon B.V. Verfahren zur herstellung von olanzapin form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (de) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Olanzapinreinigungsverfahren
US8778960B2 (en) 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
CA2882595C (en) 2012-08-21 2019-06-04 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine haptens and use thereof
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
TW268005B (de) * 1992-05-29 1996-01-11 Lilly Industries Ltd
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
DE19681286T1 (de) 1998-04-02
FI973750A (fi) 1997-09-22
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
AT406771B (de) 2000-08-25
IS1896B (is) 2003-10-20
DK1445259T3 (da) 2006-10-16
EA199700262A1 (ru) 1998-02-26
DE69636313D1 (de) 2006-08-10
UA44765C2 (uk) 2002-03-15
AU706471B2 (en) 1999-06-17
PT733635E (pt) 2001-12-28
ATE331719T1 (de) 2006-07-15
MX9707183A (es) 1997-11-29
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
ES2266719T3 (es) 2007-03-01
TR199701017T1 (xx) 1998-01-21
ATA902196A (de) 2000-01-15
CO4650278A1 (es) 1998-09-03
SI1095941T1 (en) 2003-12-31
YU49478B (sh) 2006-05-25
DK0733635T3 (da) 2001-10-08
SI0733635T1 (en) 2002-06-30
ES2208220T3 (es) 2004-06-16
CA2214005C (en) 2001-07-03
HK1013988A1 (en) 1999-09-17
ZA962342B (en) 1997-09-22
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
AR002719A1 (es) 1998-04-29
EA000149B1 (ru) 1998-10-29
OA10510A (en) 2002-04-24
NZ306110A (en) 1998-09-24
DE69614426D1 (de) 2001-09-20
PE44897A1 (es) 1997-10-22
EP1445259A1 (de) 2004-08-11
LT4349B (lt) 1998-05-25
EP0733635A1 (de) 1996-09-25
EP1445259B1 (de) 2006-06-28
TW513432B (en) 2002-12-11
AP828A (en) 2000-04-28
RO118872B1 (ro) 2003-12-30
BG101900A (en) 1999-03-31
KR19980703188A (ko) 1998-10-15
EP1095941A1 (de) 2001-05-02
LV12018B (en) 1998-09-20
US5736541A (en) 1998-04-07
HU224989B1 (en) 2006-05-29
NO974365L (no) 1997-09-22
EE03489B1 (et) 2001-08-15
BR9607790A (pt) 1998-07-07
DE69630324D1 (de) 2003-11-13
SK284143B6 (sk) 2004-10-05
CH690579A5 (de) 2000-10-31
PL322501A1 (en) 1998-02-02
ATE204280T1 (de) 2001-09-15
EP1095941B1 (de) 2003-10-08
SI1445259T1 (sl) 2006-10-31
EG23659A (en) 2007-03-26
GB2313835A (en) 1997-12-10
PT1095941E (pt) 2004-02-27
JPH11502535A (ja) 1999-03-02
CN1065536C (zh) 2001-05-09
LU90096B1 (fr) 1997-07-22
IS4564A (is) 1997-09-22
SE9703205D0 (sv) 1997-09-05
SK121897A3 (en) 1998-03-04
DE69614426T2 (de) 2002-05-23
IL117610A0 (en) 1996-07-23
SE9703205L (sv) 1997-09-05
ES2159346T3 (es) 2001-10-01
CZ300097A3 (en) 1997-12-17
EE9700232A (et) 1998-04-15
SI9620040A (sl) 1998-06-30
MY114701A (en) 2002-12-31
TW442488B (en) 2001-06-23
DE69636313T2 (de) 2007-05-31
AU5427996A (en) 1996-10-16
LT97148A (en) 1998-01-26
EP0733635B1 (de) 2001-08-16
PL183723B1 (pl) 2002-07-31
SI9620040B (sl) 2002-02-28
CA2214005A1 (en) 1996-10-03
CN1179160A (zh) 1998-04-15
GB9719819D0 (en) 1997-11-19
FI973750A0 (fi) 1997-09-22
HUP9802824A3 (en) 2000-01-28
DK108997A (da) 1997-11-12
BG62619B1 (bg) 2000-03-31
HUP9802824A2 (hu) 1999-06-28
LV12018A (lv) 1998-04-20
ZA962344B (en) 1997-09-22
KR100399688B1 (ko) 2004-02-18
DE69630324T2 (de) 2004-07-29
ATE251627T1 (de) 2003-10-15
CZ292688B6 (cs) 2003-11-12
SV1996000031A (es) 1998-03-27
NO314663B1 (no) 2003-04-28
YU17796A (sh) 1999-03-04
GB2313835B (en) 1998-09-16
DK1095941T3 (da) 2004-02-16

Similar Documents

Publication Publication Date Title
IL117610A (en) Crystal forms of form ii olanzapine and process for their preparation
HUP9600255A1 (en) Various forms of paroxetin hydrochloride and process for their preparation
PL299105A1 (en) Hygenic suspensory and method of making same
ZA9610005B (en) Container and method of making same
PL326158A1 (en) Frame and method of making same
EP0761718A3 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
HUP9600321A1 (en) Process for preparation of n-substituted cyclic-imide-derivatives
PL320340A1 (en) Optical lanses and method of making them
EP0761721A3 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
PL316704A1 (en) Method of and apparatus for making glass
HUP9601261A3 (en) Process for preparation of 2-fluor-pirimidine-derivatives
PL325515A1 (en) Pultry egg and method of producing same
EP0821576A4 (de) Verhütungsverfahren
EP0761719A3 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
EP0761720A3 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
GB2297575B (en) Reflective block and method of manufacture
EG20782A (en) Process of preparation streptogramines
ZA965023B (en) N-substituted cis-n-propenyl-acetamides and process for their preparation
HUP9900912A3 (en) Process for the preparation of 2-aryl-benzo[b]thiophene derivatives and their intermediates
HUP9900903A3 (en) Process for the preparation of 2-aryl-benzo[b]thiophene derivatives and their intermediates
ZA9610766B (en) Multimeric forms of il-16 process for their manufacture and use
AU6754296A (en) Crystal of hydrate and process for preparation thereof
GB9504419D0 (en) Articles and method of their manufacture
HU9401671D0 (en) Flavovred milk-analogs and process for making of it
IL158857A0 (en) Processes for preparation of steroids and intermediate useful therein

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees